In-vitro dosimetric analysis revealed that the relative biological effectiveness (RBE) of the Auger-emitting [125I]KX1 in comparison to low-LET beta emitting [131I]KX1 was lowest in BRCA1 mutant ovarian cancers SNU-251 and UWB1.289 (Figure 3B). The gene discussed is BRCA1; the disease is ovarian carcinoma.